Last reviewed · How we verify

NCT03512821

A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions

Completed Phase 1 Last updated 7 May 2018
What this trial tests

Phase 1 trial testing Ursodiol 500 MG in Healthy in 77 participants. Completed in 30 November 2017.

Timeline
1 October 2017
Primary endpoint
30 November 2017
30 November 2017

Quick facts

Lead sponsorDaewoong Pharmaceutical Co. LTD.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment77
Start date1 October 2017
Primary completion30 November 2017
Estimated completion30 November 2017
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Daewoong Pharmaceutical Co. LTD. — full company profile →

Who can join

18 and older, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

single-dose, comparative bioavailability study of two formulations of ursodiol 500mg tablets under fed conditions

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ursodiol 500 MG

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Daewoong Pharmaceutical Co. LTD. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03512821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing